ClinConnect ClinConnect Logo
Search / Trial NCT06315725

Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D)

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Mar 12, 2024

Trial Information

Current as of August 28, 2025

Recruiting

Keywords

Type 1 Diabetes Artificial Pancreas Artificial Sweeteners Non Nutritive Sweeteners Cross Over Taste Perception Indirect Calorimetry Insulin Glucose Metabolism

ClinConnect Summary

This clinical trial is studying how artificial sweeteners, specifically sucralose, affect insulin release and glucose metabolism in people with type 1 diabetes (T1D). Researchers want to find out if consuming carbohydrates along with non-nutritive sweeteners (which don’t provide calories) changes the way the body responds to insulin. The trial will involve participants using an artificial pancreas system, which helps monitor their glucose and insulin levels closely while they drink different flavored beverages that may or may not block sweet taste signals.

To be eligible for this study, participants must be adults aged 18 to 45 with a diagnosis of T1D, an HbA1C level of 8% or lower, and currently using insulin pump therapy. They should also have a body mass index (BMI) within a certain range and be able to consume chicken and fish. During the trial, participants will rate the sweetness of the beverages they drink and have their glucose and insulin levels monitored. This study aims to gather valuable insights that could help improve management strategies for individuals living with T1D.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants with a diagnosis of T1D
  • HbA1C ≤ 8 %
  • Insulin pump therapy
  • Adults of any gender or biological sex aged 18-45 years old,
  • Body Mass Index (BMI) between 18.5-29.9 kg/m,
  • Non-smokers,
  • English or French speaker. ●. Who can consume chicken and fish
  • Exclusion Criteria:
  • A major medical diagnosis that could potentially influence metabolic dysfunction
  • A major medical diagnosis other than T1D,
  • Alcohol or substance use disorder,
  • Eating disorder or history of malabsorptive syndrome,
  • Inflammatory bowel disease,
  • Self-reported impairment in taste or smell,
  • A known taste or smell dysfunction (e.g., anosmia),
  • Active pregnancy and/or lactation,
  • Food allergies or intolerances,
  • Dislike of the test beverages,
  • History of bariatric surgery at any point in the past ●. Regular consumer of Gymnema sylvestre

About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre

The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.

Locations

Montreal, Quebec, Canada

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported